Microtransplantation for Acute Myeloid Leukemia

Pan, Bin; Lazarus, Hillard M.; Gale, Robert Peter

doi:10.1001/jamaoncol.2020.1706

Cited by 7 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the allogeneic transplant setting, HLA matching paired with pre-transplant myeloablation reduces the risk of graft rejection, and post-transplant immunosuppression can prevent graft-versus-host disease (GVHD). Notably, UCB for transplantation with the end goal of HSC engraftment is entirely different from UCB infusions [13], particularly for neurological conditions where the goal is immunomodulation.…”

Section: Introductionmentioning

confidence: 99%

Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies

et al. 2022

View full text Add to dashboard Cite

Background aims: Umbilical cord blood (UCB) infusion is being investigated as a treatment for a range of neurological conditions, primarily because of its potent immunomodulatory effects mediated via paracrine signaling. Although initial research mainly utilized autologous UCB, allogeneic samples from a sibling or unrelated donor have now become more common. With the use of allogeneic UCB, questions have arisen surrounding the necessity for human leukocyte antigen (HLA) matching, preparative regimens and immunosuppressant drugs. To investigate the safety of allogeneic UCB for the treatment of neurological conditions and the impact of HLA mismatching and immunosuppresion, the authors conducted a systematic review of the safety of allogeneic UCB infusion for neurological conditions. Methods: A systematic review of published and gray literature was conducted to investigate the safety of allogeneic UCB infusions for neurological conditions. Results: Authors identified 10 studies using allogeneic UCB to treat autism spectrum disorder, cerebral palsy, stroke, traumatic brain injury and various other conditions. A total of 361 participants (with at least 442 UCB infusions) received a range of HLA-matched/untyped allogeneic units and cell doses, with the majority not administered post-infusion immunosuppression. There were no reported serious adverse events definitely or probably related to the allogeneic UCB infusion, nor later potential complications such as graft-versushost disease or teratoma formation. Conclusions: Although variability between studies is high, the available data do not identify safety concerns with allogeneic UCB infusion for the treatment of neurological conditions, even with variable HLA matching or no immunosuppression.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…And 7 patients of the mean age 31.3 years old got microtransplantaion without significant GVHD ( 11 ). However, safety and effectiveness of microtransplantation are still under dispute and need to be evaluated in large randomized clinical trials ( 16 ).…”

Section: Discussionmentioning

confidence: 99%

Microtransplantation for myeloid sarcoma: Two case reports

Zhang

Wang

et al. 2022

Leukemia Research Reports

View full text Add to dashboard Cite

“…Furthermore, only 23 records could be identified and only 5 papers could be included. On the other hand, few identified records [68,69] and very few [70][71][72][73][74] or no [75,76] included studies are not unusual in systematic reviews. Also, the included papers have a relatively low level of evidence (CS design) and moreover 1 paper [36] used only a small convenient sample of a major city and 3 papers [38][39][40] are only representatives of a medium-sized city.…”

Section: Strengths and Limitations Of The Reviewmentioning

confidence: 99%

Using the Simulated Patient Methodology to Assess the Quality of Counselling in German Community Pharmacies: A Systematic Review From 2005 to 2018

Kunow

Langer

2021

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

The simulated patient methodology (SPM) is a form of participatory observation and can be used to assess the quality of counselling. The aim is to review those papers reporting the use of the SPM in German community pharmacies (CPs) from the beginning of 2005 to the end of 2018. The reporting items in the study were derived from the PRISMA Statement. We conducted a systematic search in the GVK-Plus, Embase, Web of Science, PubMed and Google Scholar databases. Additional sources included the personal literature collection of 1 of the reviewers and the reference lists from international systematic reviews and potentially relevant papers. The quality of the papers included was evaluated using the AXIS tool. A total of 5 papers were included. The SPM that was used varied greatly in the papers. The quality of counselling was assessed in the papers as being rather poor. The quality of the papers differed for specific assessment criteria. Only an extremely small number of papers could be included, in contrast to other countries. The papers for Germany demonstrate that there is a considerable need for improvement in the quality of counselling in CPs. Also, the deficits identified here for the application of the SPM should be avoided in future papers. It must also be recommended that the SPM be reported in future papers using uniform reporting standards, which are yet to be developed, to ensure better comparability.

show abstract

Microtransplantation for Acute Myeloid Leukemia

Cited by 7 publications

References 57 publications

Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies

Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies

Microtransplantation for myeloid sarcoma: Two case reports

Using the Simulated Patient Methodology to Assess the Quality of Counselling in German Community Pharmacies: A Systematic Review From 2005 to 2018

Contact Info

Product

Resources

About